Sorrento Therpt (SRNE)
$9.85 0.35 (3.68%)
4:18 EST SRNE Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 1.14B
PE Ratio 49.25
Volume (Avg. Vol.) 19,486
Day's Range 9.50 - 9.50
52-Week Range 1.55 - 19.39
Dividend & Yield N/A (N/A)
SRNE Stock Predictions, Articles, and Sorrento Therpt News
- From InvestorPlace
- From the Web
Nearly a third of SRNE stock's float has been sold short. This sets up a catalyst for a short-term move, but avoid a long-term investment.
Sorrento just received a grant of up to $34 million from Washington, while multiple institutions own meaningful amounts of SRNE stock.
Sorrento Therapeutics is poised to roll out clinical testing trials in California. SRNE stock is up in pre-market trading on Wednesday as the country continues to post record Covid-19 diagnoses and hospitalizations.
Sorrento Therapeutics has seen SRNE stock close between $5.76 and $8.20 in the past month. Here’s why it’s time for investors to be careful.
SRNE stock fell out of favor as bigger vaccine developers grabbed the headlines but that may change soon.
By Thomas Niel
SRNE stock may be bouncing back, but given its grab bag of issues, skip out on this fading coronavirus play.
Sorrento Therapeutics was an early pandemic winner. But as the world closes in on multiple vaccines, SRNE stock looks to be too late.
Investors seeking a longshot coronavirus play continue to eye SRNE stock despite Sorrento Therapeutics' high risk and continued volatility.
The Covid-19 race is close to ending. It seems unlikely that Sorrento stock can pull a rabbit out of a hat with the frontrunners emerging.
Thanks to Sorrento Therapeutics’ all-out pivot to address the Covid-19 pandemic, SRNE stock initially became one of the most popular investments. But as both the vaccine and treatment race tighten, the risks multiply.
SRNE stock has tumbled as larger players have shown progress toward a vaccine. But this isn't just a vaccine play, and the story is far from over.
Avoid Sorrento Therapeutics which is still burning cash with no end in sight. SRNE stock will become more diluted as the company consistently raises cash.
As Pfizer and Moderna take the lead in the novel coronavirus vaccine race, here’s how this affects other Covid-19-related biotech stocks.
In this competition, Sorrento is a different beast because it's not just working on a vaccine, it's working on Covid-19 testing, neutralizing antibodies and preventive “shields,” among other products. That's a relevant, robust pipeline, but it hasn't been enough to prevent SRNE stock from sliding 61% from its 52-week high.
If you'd like to wager on a company with a packed clinical pipeline featuring potential Covid-19 treatments, SRNE stock is a great choice.
Sorrento stock continues to be weighed down by the company's inefficacious product pipeline making it an incredibly risky investment.
SRNE stock is a speculative play in the race to develop a Covid-19 therapy
Sorrento stock has lost 50% over the past month. Investors have grown impatient with the company's Covid-19 efforts. Time to buy or sell?
SRNE stock is a purely speculative bet. The company has a deep pipeline of Covid-19 programs. But there is little progress or positive outcome.
From Talk Markets
From Market News Video
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sorrento Therapeutics Inc (SRNE), where a total of 78,707 contracts have traded so far, representing approximately 7.9 million underlying shares. That amounts to about 61.1% of SRNE's average daily trading volume over the past month of 12.9 million shares..
Navellier RatingsPowered by Portfolio Grader